143 related articles for article (PubMed ID: 29486625)
1. Management of relapsed or refractory follicular lymphoma patients in daily practice - a French non-interventional study.
Feugier P; Brice P; Maynadié M; Franchi-Rezgui P; Hacini M; Laurent G; Suc E; Fitoussi O; Solal-Celigny P; Damaj G; Haioun C; Leconte P; Lazreg F; Boissard F; Pau D; Salles G
Leuk Lymphoma; 2018 Oct; 59(10):2485-2488. PubMed ID: 29486625
[No Abstract] [Full Text] [Related]
2. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
Gibiansky E; Gibiansky L; Buchheit V; Frey N; Brewster M; Fingerle-Rowson G; Jamois C
Br J Clin Pharmacol; 2019 Sep; 85(9):1935-1945. PubMed ID: 31050355
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study.
Salles G; Schuster SJ; de Vos S; Wagner-Johnston ND; Viardot A; Blum KA; Flowers CR; Jurczak WJ; Flinn IW; Kahl BS; Martin P; Kim Y; Shreay S; Will M; Sorensen B; Breuleux M; Zinzani PL; Gopal AK
Haematologica; 2017 Apr; 102(4):e156-e159. PubMed ID: 27979923
[No Abstract] [Full Text] [Related]
4. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.
Taverna C; Martinelli G; Hitz F; Mingrone W; Pabst T; Cevreska L; Del Giglio A; Vanazzi A; Laszlo D; Raats J; Rauch D; Vorobiof DA; Lohri A; Biaggi Rudolf C; Rondeau S; Rusterholz C; Heijnen IA; Zucca E; Ghielmini M
J Clin Oncol; 2016 Feb; 34(5):495-500. PubMed ID: 26712227
[TBL] [Abstract][Full Text] [Related]
5. Randomized controlled trials in relapsed/refractory follicular lymphoma: a systematic review and meta-analysis.
Police RL; Trask PC; Wang J; Olivares R; Khan S; Abbe A; Colosia A; Njue A; Sherril B; Ruiz-Soto R; Kaye JA; Hamadani M
J Oncol Pharm Pract; 2016 Oct; 22(5):666-78. PubMed ID: 26320127
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma.
Hess G; Keller U; Scholz CW; Witzens-Harig M; Atta J; Buske C; Kirschey S; Ruckes C; Medler C; van Oordt C; Klapper W; Theobald M; Dreyling M
Leukemia; 2015 Aug; 29(8):1695-701. PubMed ID: 25765545
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.
Fowler N; Kahl BS; Lee P; Matous JV; Cashen AF; Jacobs SA; Letzer J; Amin B; Williams ME; Smith S; Saleh A; Rosen P; Shi H; Parasuraman S; Cheson BD
J Clin Oncol; 2011 Sep; 29(25):3389-95. PubMed ID: 21810687
[TBL] [Abstract][Full Text] [Related]
9. Advances in Treatment of Follicular Lymphoma.
Luminari S; Trotman J; Federico M
Cancer J; 2020; 26(3):231-240. PubMed ID: 32496456
[TBL] [Abstract][Full Text] [Related]
10. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Mey UJ; Orlopp KS; Flieger D; Strehl JW; Ho AD; Hensel M; Bopp C; Gorschlüter M; Wilhelm M; Birkmann J; Kaiser U; Neubauer A; Florschütz A; Rabe C; Hahn C; Glasmacher AG; Schmidt-Wolf IG
Cancer Invest; 2006 Oct; 24(6):593-600. PubMed ID: 16982464
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study on the management of patients with rituximab refractory follicular lymphoma.
Solal-Céligny P; Leconte P; Bardet A; Hernandez J; Troussard X
Br J Haematol; 2018 Jan; 180(2):217-223. PubMed ID: 29230799
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.
Craig M; Hanna WT; Cabanillas F; Chen CS; Esseltine DL; Neuwirth R; O'Connor OA
Br J Haematol; 2014 Sep; 166(6):920-8. PubMed ID: 25039282
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US.
Guzauskas GF; Masaquel A; Reyes C; Bernaards C; Krivasi T; Veenstra DL
J Med Econ; 2018 Oct; 21(10):960-967. PubMed ID: 29898619
[TBL] [Abstract][Full Text] [Related]
14. Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma.
Ito K; Okamoto M; Ando M; Kakumae Y; Okamoto A; Inaguma Y; Tokuda M; Yanada M; Yamada S; Emi N
Leuk Lymphoma; 2015 Apr; 56(4):1123-5. PubMed ID: 24828861
[No Abstract] [Full Text] [Related]
15. Management of relapsed/refractory follicular lymphoma.
Martin P
Clin Adv Hematol Oncol; 2018 Apr; 16 Suppl 10(4):1-12. PubMed ID: 29851937
[No Abstract] [Full Text] [Related]
16. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
Fowler NH; Davis RE; Rawal S; Nastoupil L; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale MA; Fayad LE; Westin JR; Shah J; Orlowski RZ; Wang M; Turturro F; Oki Y; Claret LC; Feng L; Baladandayuthapani V; Muzzafar T; Tsai KY; Samaniego F; Neelapu SS
Lancet Oncol; 2014 Nov; 15(12):1311-8. PubMed ID: 25439689
[TBL] [Abstract][Full Text] [Related]
17. Progressive multifocal leukoencephalopathy in patients with follicular lymphoma treated with bendamustine plus rituximab followed by rituximab maintenance.
D'Alò F; Malafronte R; Piludu F; Bellesi S; Cuccaro A; Maiolo E; Modoni A; Leccisotti L; Macis G; Mores N; De Stefano V; Hohaus S
Br J Haematol; 2020 May; 189(4):e140-e144. PubMed ID: 32150646
[No Abstract] [Full Text] [Related]
18. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity.
Cheah CY; Nastoupil LJ; McLaughlin P; Fanale MA; Neelapu SS; Fayad LE; Hagemeister FB; Fowler NH
Br J Haematol; 2016 Nov; 175(3):531-533. PubMed ID: 26683805
[No Abstract] [Full Text] [Related]
19. Follicular Lymphoma: Redefining Prognosis, Current Treatment Options, and Unmet Needs.
Welaya K; Casulo C
Hematol Oncol Clin North Am; 2019 Aug; 33(4):627-638. PubMed ID: 31229159
[TBL] [Abstract][Full Text] [Related]
20. Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma.
Hainsworth JD; Greco FA; Raefsky EL; Thompson DS; Lunin S; Reeves J; White L; Quinn R; DeBusk LM; Flinn IW
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):277-83. PubMed ID: 24679633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
